Загрузка...
A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay
Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer is challenging. The Oncotype DX gene assay is often used. Using a database of 221 patients a simple 2-rule model was developed and validated on an independent group of 319 patients. The model categorizes patients unlike...
Сохранить в:
| Опубликовано в: : | Clin Breast Cancer |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4847530/ https://ncbi.nlm.nih.gov/pubmed/26072275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2015.04.006 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|